FDA Closed Zenzi Pharmaceutical Compliance Matter
Federal regulators have resolved a specific warning letter but maintained an existing import alert.
Updated on Sept. 24, 2026 in Healthcare
Live Poll
Should foreign pharmaceutical companies be required to permit onsite inspections to sell in the U.S.?
The Food and Drug Administration has closed its compliance matter regarding Zenzi Pharmaceutical Industries Private Limited following a review of the firm's responses. However, the agency has kept the manufacturer on Import Alert 66-79 due to outstanding verification concerns.
Why it matters
The FDA maintains import alerts to prevent products from entering the U.S. market when a firm's compliance with current good manufacturing practices remains unverified. This action highlights the ongoing regulatory oversight of foreign pharmaceutical manufacturers that refuse onsite inspections.
The agency resolved the matter linked to Warning Letter 320-25-45, but the firm remains subject to Import Alert 66-79. Zenzi Pharmaceutical does not currently manufacture human drugs for the U.S. market.
The players
Food and Drug Administration
This is the federal agency responsible for protecting public health by ensuring the safety and efficacy of drugs and medical products in the United States.
Zenzi Pharmaceutical Industries Private Limited
This is the pharmaceutical manufacturing firm that has been subject to federal warning letters and import restrictions.
The details
The FDA closed the active matter involving Warning Letter 320-25-45 and a 704(a)(4) records request after evaluating the company's submissions. The firm continues to be excluded from standard U.S. market participation because it has indicated it is unwilling to submit to an onsite inspection to verify its adherence to current good manufacturing practices.
Timeline
February 13, 2025: The FDA issued Warning Letter 320-25-45 to the firm.
May 22, 2026: The FDA issued a 704(a)(4) request for company records.
September 18, 2026: The agency officially closed the compliance matter.
Market Landscape
This enforcement action aligns with the FDA's broader oversight framework, which relies on the Import Alert 66-79 mechanism to manage risks from foreign suppliers. The case follows the pattern of maintaining strict barriers for manufacturers that refuse the site access required to operate within the U.S. healthcare supply chain.
Because the firm does not produce human drugs for the U.S. market, this regulatory action does not directly change current drug availability or retail pharmacy inventories. The FDA's continued use of the import alert ensures that no products from this specific manufacturer are distributed to American patients until standards are met.
The takeaway
Regulatory compliance is a prerequisite for entering the U.S. pharmaceutical market, and the FDA continues to enforce this by restricting access to firms that decline onsite inspections. Consumers can remain confident that imported drugs under such alerts are kept out of the domestic supply chain.
Further reading
For more on the regulations governing international medical supplies, see the Healthcare section.
More information
View the official FDA warning letter record for full documentation.
Live Poll
Should foreign pharmaceutical companies be required to permit onsite inspections to sell in the U.S.?
